OBJECTIVES: This study was designed to determine the enhancement profile of a necrosis-specific contrast agent (gadophrin III) in comparison to a standard extracellular agent on T1-weighted magnetic resonance (MR) images in acute and chronic myocardial infarctions (MIs). BACKGROUND: Contrast-enhanced MR imaging demonstrated the ability to accurately quantify infarct size; however, some controversies persist about which contrast medium is best suited. METHODS: Fifteen rabbits underwent thoracotomy and permanent occlusion of a branch of the left coronary artery. Two animals died before imaging, eight were examined 48 h after occlusion and five animals were imaged six weeks following induction of infarction. All animals received 50 micromol/kg of gadophrin-3 24 h before the MR examination. Continuous short-axis views were collected using an inversion recovery turbo fast low angle shot sequence. Imaging was repeated 5 to 10 min following additional injection of 100 micromol/kg of Magnevist. The area of hyperenhancement demarcated following gadophrin-3 injection was compared with the region of hyperenhancement seen on gadophrin-3 plus Magnevist enhanced image using triphenyltetrazolium chloride (TTC) staining as the standard of reference. RESULTS: In acute MI the mean difference in size of hyperenhancement seen on the two different in vivo MR scans was -1.8 +/- 6.0 mm(2) (p > 0.05). Both measurements showed excellent agreement with TTC staining. Chronic MIs showed no enhancement with gadophrin-3, whereas application of Magnevist resulted in hyperenhancement. CONCLUSIONS; Standard extracellular contrast agents do not overestimate the size of acute MI. The combination of gadophrin-3 and Magnevist can distinguish acute and chronic myocardial injury because chronic MIs do not enhance with gadophrin-3.
OBJECTIVES: This study was designed to determine the enhancement profile of a necrosis-specific contrast agent (gadophrin III) in comparison to a standard extracellular agent on T1-weighted magnetic resonance (MR) images in acute and chronic myocardial infarctions (MIs). BACKGROUND: Contrast-enhanced MR imaging demonstrated the ability to accurately quantify infarct size; however, some controversies persist about which contrast medium is best suited. METHODS: Fifteen rabbits underwent thoracotomy and permanent occlusion of a branch of the left coronary artery. Two animals died before imaging, eight were examined 48 h after occlusion and five animals were imaged six weeks following induction of infarction. All animals received 50 micromol/kg of gadophrin-3 24 h before the MR examination. Continuous short-axis views were collected using an inversion recovery turbo fast low angle shot sequence. Imaging was repeated 5 to 10 min following additional injection of 100 micromol/kg of Magnevist. The area of hyperenhancement demarcated following gadophrin-3 injection was compared with the region of hyperenhancement seen on gadophrin-3 plus Magnevist enhanced image using triphenyltetrazolium chloride (TTC) staining as the standard of reference. RESULTS: In acute MI the mean difference in size of hyperenhancement seen on the two different in vivo MR scans was -1.8 +/- 6.0 mm(2) (p > 0.05). Both measurements showed excellent agreement with TTC staining. Chronic MIs showed no enhancement with gadophrin-3, whereas application of Magnevist resulted in hyperenhancement. CONCLUSIONS; Standard extracellular contrast agents do not overestimate the size of acute MI. The combination of gadophrin-3 and Magnevist can distinguish acute and chronic myocardial injury because chronic MIs do not enhance with gadophrin-3.
Authors: Mathias Goyen; Susanne C Goehde; Christoph U Herborn; Peter Hunold; Florian M Vogt; Elke R Gizewski; Thomas C Lauenstein; Waleed Ajaj; Michael Forsting; Jörg F Debatin; Stefan G Ruehm Journal: Eur Radiol Date: 2004-02-13 Impact factor: 5.315
Authors: Abhinav Diwan; Maike Krenz; Faisal M Syed; Janaka Wansapura; Xiaoping Ren; Andrew G Koesters; Hairong Li; Lorrie A Kirshenbaum; Harvey S Hahn; Jeffrey Robbins; W Keith Jones; Gerald W Dorn Journal: J Clin Invest Date: 2007-10 Impact factor: 14.808
Authors: Daniel Thomas; Harshali Bal; Jeffrey Arkles; James Horowitz; Luis Araujo; Paul D Acton; Victor A Ferrari Journal: Magn Reson Med Date: 2008-02 Impact factor: 4.668